Jack Khouri
YOU?
Author Swipe
View article: Table S7 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S7 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 7: Univariable regression for overall response
View article: Table S9 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S9 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table S9: Univariable and multivariable regression for ≥VGPR
View article: Table S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 1: Reasons for MajesTEC-1 ineligibility
View article: Table S12 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S12 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 12: Progression-free survival in prognostic subsets
View article: Figure S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Figure S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
PFS in prognostic subsets
View article: Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 2: Prior BCMA-directed therapy details
View article: Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Relationship between PFS and time from last BCMA-directed therapy or serum ferritin
View article: Table S6 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S6 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 6. Best Overall Response
View article: Table S4 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S4 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 4. CRS features
View article: Table S10 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S10 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table S10: Teclistamab responses and univariable and multivariable associations by prior BCMA exposure
View article: Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era
Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era Open
Introduction: Patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM) often receive urgent chemotherapy (chemo) in the inpatient (inpt) setting for disease progression (PD). The long-term benefits and outcomes of such intervent…
View article: Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)
Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM) Open
Background: Real-world data suggest that safety and efficacy of ide-cel and cilta-cel mirror data from pivotal trials, yet older adults remain underrepresented. We report outcomes of the largest cohort of RRMM patients aged ≥75 years recei…
View article: Table S9 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S9 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table S9: Univariable and multivariable regression for ≥VGPR
View article: Data from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Data from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US …
View article: Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)
Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM) Open
Background: IEC-HS is a potentially life-threatening complication following CAR-T therapy in RRMM. Reliable diagnostic biomarkers are needed to help expeditiously identify cases to initiate prompt treatment and supportive care. Serum ferri…
View article: Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Figure S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Relationship between PFS and time from last BCMA-directed therapy or serum ferritin
View article: Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells
Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells Open
Introduction: Novel therapeutic approaches, especially cellular therapies, have significantly prolonged the survival of patients with multiple myeloma (MM). However, a cure is yet to be discovered, and the natural course of myeloma remains…
View article: Table S11 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S11 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 11. Progression Free Survival Univariable and Multivariable Regression Analyses
View article: Table S3 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S3 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table S3: Baseline characteristics by prior BCMA-directed therapy
View article: Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium
Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium Open
Introduction: Ciltacabtagene autoleucel (cilta-cel) is a highly effective BCMA-redirected CAR T-cell therapy for RRMM. While the pivotal CARTITUDE-1 trial established a target dose of 0.75 x 10^6 CAR+ viable T-cells/kg, the approved cell d…
View article: Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S2 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 2: Prior BCMA-directed therapy details
View article: Table S13 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S13 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table S13: Progression-free survival univariable and multivariable regression analyses among patients with ≥VGPR
View article: Table S12 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S12 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 12: Progression-free survival in prognostic subsets
View article: Table S5 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S5 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table S5: Multiple myeloma responses
View article: Table S7 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S7 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 7: Univariable regression for overall response
View article: Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning
Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning Open
Background In systemic light chain (AL) amyloidosis, hematologic remission does not guarantee organ recovery. Discordance between hematologic and end organ responses is clinically relevant but remains poorly characterized. We sought to ide…
View article: A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results
A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results Open
Background: Rapid and deep normalization of involved free light chains (iFLC) is necessary for organ response and attendant survival in AL amyloidosis patients. There are no FDA-approved treatment options for relapsed patients. Elranatamab…
View article: Table S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 1: Reasons for MajesTEC-1 ineligibility
View article: Table S4 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Table S4 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
Supplemental Table 4. CRS features
View article: Figure S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Figure S1 from Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium Open
PFS in prognostic subsets